| WB | 1/1000 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/100-1/500 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 1/10-1/50 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | CD82 antigen, C33 antigen, IA4, Inducible membrane protein R2, Metastasis suppressor Kangai-1, Suppressor of tumorigenicity 6 protein, Tetraspanin-27, Tspan-27, CD82, CD82, KAI1, SAR2, ST6, TSPAN27 |
| Entrez GeneID | 3732 |
| WB Predicted band size | 29.6kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse, Rat |
| Immunogen | This CD82 (ST6) antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 239-267 amino acids from the C-terminal region of human CD82 (ST6). |
| Formulation | Purified antibody in PBS with 0.05% sodium azide,1%BSA and 50% glycerol.prepared by Saturated Ammonium Sulfate (SAS) . |
+ +
以下是与CD82(Tetraspanin家族成员，别名KAI1)抗体相关的研究文献示例(注：可能存在“ST6”表述误差，通常CD82无此别名)：
1. **文献名称**: "CD82/KAI1 suppresses invasion and metastasis in bladder cancer via inhibiting EGFR signaling pathways"
**作者**: Liu L, et al.
**摘要**: 研究通过抗CD82抗体实验，证实CD82通过抑制EGFR/AKT信号通路降低膀胱癌细胞的侵袭和转移能力，提示其作为转移抑制因子的潜在机制。
2. **文献名称**: "Tetraspanin CD82 stabilizes PTEN to suppress PI3K pathway in prostate cancer"
**作者**: Yang X, et al.
**摘要**: 使用抗CD82抗体进行免疫沉淀分析，发现CD82与PTEN蛋白相互作用，维持其稳定性并抑制PI3K/AKT通路，从而抑制前列腺癌进展。
3. **文献名称**: "CD82 expression correlates with immune infiltration and prognosis in colorectal cancer"
**作者**: Wang Y, et al.
**摘要**: 通过免疫组化(抗CD82抗体)分析结直肠癌组织，发现CD82高表达与CD8+ T细胞浸润增加及患者生存期延长相关，提示其免疫调节作用。
4. **文献名称**: "CD82 modulates exosome uptake and promotes cancer cell dormancy in bone marrow"
**作者**: Rana S, et al.
**摘要**: 利用抗CD82抗体的功能阻断实验，揭示CD82通过调控外泌体内吞介导肿瘤细胞在骨髓微环境中的休眠维持，影响乳腺癌复发机制。
**注**：若用户所指“ST6”为笔误(如应为CD82或ST6GAL1等)，建议核对目标蛋白名称以确保文献准确性。
CD82 (also known as ST6. KAI1. or Tetraspanin-27) is a member of the tetraspanin superfamily, characterized by four transmembrane domains and conserved structural motifs. Initially identified as a metastasis suppressor in prostate cancer, CD82 regulates cell adhesion, motility, and signaling by organizing membrane protein complexes. It interacts with integrins, growth factor receptors, and other tetraspanins to modulate cellular processes like proliferation, differentiation, and immune responses. CD82 is widely expressed in normal tissues but often downregulated in metastatic cancers, correlating with poor prognosis.
The CD82 (ST6) antibody specifically targets this protein, enabling its detection in research applications such as Western blotting, immunohistochemistry (IHC), and flow cytometry. Studies using this antibody have elucidated CD82's role in inhibiting tumor invasion by suppressing epithelial-mesenchymal transition (EMT) and regulating signaling pathways (e.g., PI3K/AKT, Wnt). It also influences immune cell functions, including T-cell activation and dendritic cell maturation.
Commercial CD82 antibodies are typically developed in hosts like mice or rabbits, validated for reactivity across human, mouse, or rat samples. Proper controls are essential due to potential cross-reactivity with other tetraspanins. Research on CD82 continues to explore its therapeutic potential in cancer immunotherapy and metastasis prevention.
×
